ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term - Pharmaceutical Technology

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented. Key opinion leaders interviewed by GlobalData were near-unanimous in recognising tirzepatide as the current best-in-class obesity therapy. Continuation of tirzepatide at either MTD or 5mg was statistically and clinically superior to placebo across primary and key secondary endpoints. Credit: joshimerbin via Shutterstock.com. On May 13, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase III SURMOUNT-MAINTAIN trial (NCT06047548) were presented, evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss following…

GlobalData Healthcare · 2026-05-15

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.

Source: Pharmaceutical Technology